MX2020003385A - Vectores adenovirales de replicacion competente. - Google Patents
Vectores adenovirales de replicacion competente.Info
- Publication number
- MX2020003385A MX2020003385A MX2020003385A MX2020003385A MX2020003385A MX 2020003385 A MX2020003385 A MX 2020003385A MX 2020003385 A MX2020003385 A MX 2020003385A MX 2020003385 A MX2020003385 A MX 2020003385A MX 2020003385 A MX2020003385 A MX 2020003385A
- Authority
- MX
- Mexico
- Prior art keywords
- adenoviral vectors
- replication competent
- competent adenoviral
- replication
- vectors
- Prior art date
Links
- 230000010076 replication Effects 0.000 title abstract 3
- 239000013598 vector Substances 0.000 title abstract 3
- 238000001415 gene therapy Methods 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 229940021993 prophylactic vaccine Drugs 0.000 abstract 1
- 229940021747 therapeutic vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572927P | 2017-10-16 | 2017-10-16 | |
| PCT/EP2018/078206 WO2019076877A1 (en) | 2017-10-16 | 2018-10-16 | ADENOVIRAL VECTORS FOR REPLICATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003385A true MX2020003385A (es) | 2020-10-01 |
Family
ID=63965644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003385A MX2020003385A (es) | 2017-10-16 | 2018-10-16 | Vectores adenovirales de replicacion competente. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11268108B2 (enExample) |
| EP (1) | EP3697899A1 (enExample) |
| JP (1) | JP2020537525A (enExample) |
| KR (1) | KR20200066349A (enExample) |
| CN (1) | CN111655847A (enExample) |
| AR (1) | AR113450A1 (enExample) |
| AU (1) | AU2018351308B2 (enExample) |
| BR (1) | BR112020007238A2 (enExample) |
| CA (1) | CA3079043A1 (enExample) |
| EA (1) | EA202090700A1 (enExample) |
| IL (1) | IL273753A (enExample) |
| MX (1) | MX2020003385A (enExample) |
| SG (1) | SG11202003058UA (enExample) |
| WO (1) | WO2019076877A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021025025A2 (pt) | 2019-06-11 | 2022-02-22 | Glaxosmithkline Biologicals Sa | Formulações de vacinas de mucosa |
| EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| EP4458975A3 (en) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| US20230109362A1 (en) | 2020-05-14 | 2023-04-06 | Glaxosmithkline Biologicals Sa | Viral biosensors |
| CN114591922A (zh) * | 2022-03-30 | 2022-06-07 | 长睿生物技术(成都)有限公司 | 一种表达狂犬病毒g蛋白的重组黑猩猩源腺病毒及其制备方法 |
| CN119677546A (zh) | 2022-07-12 | 2025-03-21 | 吉利德科学公司 | Hiv免疫原性多肽和疫苗及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998010087A1 (en) * | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| MX2011007980A (es) | 2009-02-02 | 2011-08-17 | Okairos Ag | Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas. |
| US8865182B2 (en) * | 2009-07-31 | 2014-10-21 | Paxvax, Inc. | Adenoviral-based vectors |
| JP6091435B2 (ja) | 2011-02-22 | 2017-03-08 | カリフォルニア インスティチュート オブ テクノロジー | アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達 |
| GB201322851D0 (en) * | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| EA038402B9 (ru) | 2015-06-12 | 2021-09-22 | Глаксосмитклайн Байолоджикалс Са | Аденовирусные полинуклеотиды и полипептиды |
| GB201513010D0 (en) * | 2015-07-23 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel formulation |
| GB201513176D0 (en) * | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| GB201620968D0 (en) * | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
-
2018
- 2018-10-16 SG SG11202003058UA patent/SG11202003058UA/en unknown
- 2018-10-16 KR KR1020207013668A patent/KR20200066349A/ko not_active Withdrawn
- 2018-10-16 BR BR112020007238-9A patent/BR112020007238A2/pt not_active IP Right Cessation
- 2018-10-16 AU AU2018351308A patent/AU2018351308B2/en not_active Expired - Fee Related
- 2018-10-16 AR ARP180103004A patent/AR113450A1/es not_active Application Discontinuation
- 2018-10-16 CA CA3079043A patent/CA3079043A1/en active Pending
- 2018-10-16 MX MX2020003385A patent/MX2020003385A/es unknown
- 2018-10-16 EP EP18792880.9A patent/EP3697899A1/en active Pending
- 2018-10-16 EA EA202090700A patent/EA202090700A1/ru unknown
- 2018-10-16 JP JP2020521290A patent/JP2020537525A/ja active Pending
- 2018-10-16 CN CN201880080955.9A patent/CN111655847A/zh active Pending
- 2018-10-16 WO PCT/EP2018/078206 patent/WO2019076877A1/en not_active Ceased
- 2018-10-16 US US16/756,376 patent/US11268108B2/en active Active
-
2020
- 2020-04-01 IL IL273753A patent/IL273753A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200066349A (ko) | 2020-06-09 |
| CN111655847A (zh) | 2020-09-11 |
| BR112020007238A2 (pt) | 2020-10-13 |
| AU2018351308B2 (en) | 2021-12-02 |
| CA3079043A1 (en) | 2019-04-25 |
| EA202090700A1 (ru) | 2020-10-21 |
| US20210189421A1 (en) | 2021-06-24 |
| US11268108B2 (en) | 2022-03-08 |
| AR113450A1 (es) | 2020-05-06 |
| SG11202003058UA (en) | 2020-04-29 |
| IL273753A (en) | 2020-05-31 |
| AU2018351308A1 (en) | 2020-04-23 |
| JP2020537525A (ja) | 2020-12-24 |
| WO2019076877A1 (en) | 2019-04-25 |
| EP3697899A1 (en) | 2020-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003385A (es) | Vectores adenovirales de replicacion competente. | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| MX2024013018A (es) | Dianas terapeuticas para la correccion del gen de la distrofina humana por edicion genica y metodos de uso | |
| EP3998341A3 (en) | Adenoviral vectors | |
| MX2020003939A (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos. | |
| NZ737471A (en) | Hydrophilic linkers for conjugation | |
| MX2018012897A (es) | Nuevos polipeptidos biespecificos contra cd137. | |
| CA2925021C (en) | MODIFIED MESSENGER RIBONUCLE ACID (MRNA) WITH REDUCED IMMUNOSTIMULATING PROPERTIES | |
| ZA202307880B (en) | Human cytomegalovirus comprising exogenous antigens | |
| JO3556B1 (ar) | علاجات مدمجة لمعالجة السرطان | |
| MX2020010694A (es) | Particulas de raav que codifican mir-708 y usos del mismo. | |
| EP4417262A3 (en) | Combination therapy | |
| SG11202000650YA (en) | Factor viii (fviii) gene therapy methods | |
| MA52011A (fr) | Vaccins peptidiques contre l'interleukine-31 | |
| EP4406613A3 (en) | Immunogenic arginase peptides | |
| MX2020013389A (es) | Composiciones de terlipresina y usos de las mismas. | |
| EP4219525A3 (en) | Foxm1-derived peptide, and vaccine including same | |
| WO2016011432A3 (en) | Identification of immunogenic mhc class ii peptides for immune-based therapy | |
| EP3981416A3 (en) | Koc1-derived peptide and vaccine including same | |
| EA201691964A1 (ru) | Конъюгаты для доставки лекарственного средства для лечения устойчивой формы рака и для применения в комбинированной терапии | |
| SG11201907914QA (en) | Polypeptide, polypeptide fragment, derivative thereof, and applications thereof | |
| MX2021015026A (es) | Peptido derivado de urlc10 y vacuna que lo contiene. | |
| SG10201900879PA (en) | Cdca1-derived peptide and vaccine containing same | |
| HK40068232A (en) | Therapeutic viral vaccine | |
| HK40053732A (en) | Neoantigen targeting dna vaccine for combination therapy |